For Q1 FY2026 ended March 31, 2026, Mobia Medical reported revenue of $12.1 million, up 113.3% year-over-year. Net loss widened to $17.7 million from $10.6 million, a 66.5% increase. Operating loss was $16.9 million, up 64.4%. Diluted EPS was -$19.30, compared to -$12.97 a year ago. Cash stood at $55.7 million, while stockholders' equity was negative $167.7 million.
•Revenue surged 113.3% YoY to $12.1 million.
•Net loss increased 66.5% to $17.7 million.
•Operating loss rose 64.4% to $16.9 million.
•Diluted EPS was -$19.30, down from -$12.97.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Mobia Medical develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients.
The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings.
The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions patients and caregivers within the healthcare sector. Founded in 2007, the company is based in Austin, Texas.
What does Mobia Medical, Inc. (MOBI) do and what are its main products?
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, focusing on implantable systems for stroke rehabilitation and other neurological conditions. Its main product is the Vivistim System, an FDA-approved implantable device that combines vagus nerve stimulation with therapy to help post-stroke patients improve upper limb motor function. The paired VNS platform aids patients in relearning movements and reducing motor deficits. The company is also developing the platform for additional chronic neurologic conditions such as tinnitus. Mobia Medical serves healthcare professionals, patients, and caregivers involved in stroke rehabilitation and chronic neurological care.
On which stock exchange is Mobia Medical (MOBI) listed and what currency does it trade in?
Mobia Medical, Inc. is listed on the NasdaqGS exchange under the ticker symbol MOBI. The company trades in US Dollars (USD), as it is based in the United States. Being listed on a major US exchange like Nasdaq provides liquidity and visibility for investors interested in the healthcare and medical devices sector.
What sector and industry does Mobia Medical (MOBI) operate in?
Mobia Medical operates in the Healthcare sector, specifically within the Medical Devices industry. The company focuses on neurostimulation technology, developing implantable devices that use vagus nerve stimulation to treat chronic neurological conditions. As a medical device company, it is involved in the design, development, and commercialization of therapeutic devices that require regulatory approvals, such as FDA clearance for its Vivistim System.
Where is Mobia Medical (MOBI) headquartered and what markets does it serve?
Mobia Medical is headquartered in Austin, Texas, United States. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. While its primary market is the United States, its products address global needs in neurological rehabilitation. The company was founded in 2007 and has since focused on developing neurostimulation therapies to improve patient outcomes.
How does Mobia Medical (MOBI) generate revenue and what is its business model?
Mobia Medical generates revenue by commercializing its neurostimulation medical devices, primarily the Vivistim System, which is an FDA-approved implantable device for stroke rehabilitation. The company sells these devices to healthcare providers and institutions that treat patients with chronic neurological conditions. Additionally, it supports its products with information and resources for healthcare professionals, patients, and caregivers. The business model involves ongoing development of the paired VNS platform for additional indications like tinnitus, which could expand its revenue streams. As a medical device company, revenue comes from device sales and potentially from associated services or consumables.